Can I read Median Effective Dose of Esketamine for Intranasal Premedication in Children with Congenital Heart Disease on EtoBox?

Median Effective Dose of Esketamine for Intranasal Premedication in Children with Congenital Heart Disease by Jiajia Huang; Daoqing Liu; Jie Bai; Hongbin Gu is a Medicine article available to read on EtoBox.

What is Median Effective Dose of Esketamine for Intranasal Premedication in Children with Congenital Heart Disease about?

## Background Esketamine is commonly used as a premedication for its sedation effect. However, the proper dosage for intranasal use in children with congenital heart disease (CHD) has not been determined. This study aimed to estimate the median effective dose (ED~50~) of esketamine for intranasal premedication in children with CHD. ## Methods Thirty-four children with CHD who needed premedication in March 2021 were enrolled. Intranasal esketamine was initiated at a dose of 1 mg/kg. Based on the outcome of sedation in the previous patient, the dose for the subsequent patient was either increased or reduced by 0.1 mg/kg, which was adjusted between each child. Successful sedation was defined as a Ramsay Sedation Scale score ≥ 3 and Parental Separation Anxiety Scale score ≤ 2. The required ED~50~ of esketamine was calculated using the modified sequential method. Non-invasive blood pressure, heart rate, saturation of peripheral oxygen, sedation onset time, and adverse reactions were recorded at 5 min intervals after drug administration. ## Results The 34 children enrolled had a mean age of 22.5 ± 16.4 (4–54) months and a mean weight of 11.2 ± 3.6 (5.5–20.5) kg; American Society of Anest

Who reads Median Effective Dose of Esketamine for Intranasal Premedication in Children with Congenital Heart Disease?

Author

Jiajia Huang; Daoqing Liu; Jie Bai; Hongbin Gu

Publisher

Springer Science and Business Media LLC

Published

2023

Language

EN

Field

Medicine (Health Sciences)